Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa

Hdl Handle:
http://hdl.handle.net/10144/295261
Title:
Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa
Authors:
Murphy, R A; Marconi, V C; Gandhi, R T; Kuritzkes, D R; Sunpath, H
Journal:
PloS One
Abstract:
In HIV-infected patients receiving rifampicin-based treatment for tuberculosis (TB), the dosage of lopinavir/ritonavir (LPV/r) is adjusted to prevent sub-therapeutic lopinavir concentrations. In this setting, South African clinicians were advised to administer super-boosted LPV/r (400 mg/400 mg) twice daily, instead of standard dosed LPV/r (400 mg/100 mg) twice daily. We sought to determine--in routine practice--the tolerability and HIV treatment outcomes associated with super-boosted LPV/r compared to unadjusted LPV/r in combination with rifampicin-based TB treatment.
Affiliation:
Medical Unit, Médecins Sans Frontières/Doctors Without Borders, New York, New York, United States of America
Publisher:
Public Library of Science
Issue Date:
28-Sep-2012
URI:
http://hdl.handle.net/10144/295261
DOI:
10.1371/journal.pone.0044793
PubMed ID:
23028623
Submitted date:
2013-06-20
Language:
en
ISSN:
1932-6203
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorMurphy, R Aen_GB
dc.contributor.authorMarconi, V Cen_GB
dc.contributor.authorGandhi, R Ten_GB
dc.contributor.authorKuritzkes, D Ren_GB
dc.contributor.authorSunpath, Hen_GB
dc.date.accessioned2013-07-04T20:47:22Z-
dc.date.available2013-07-04T20:47:22Z-
dc.date.issued2012-09-28-
dc.date.submitted2013-06-20-
dc.identifier.citationCoadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. 2012, 7 (9):e44793 PLoS ONEen_GB
dc.identifier.issn1932-6203-
dc.identifier.pmid23028623-
dc.identifier.doi10.1371/journal.pone.0044793-
dc.identifier.urihttp://hdl.handle.net/10144/295261-
dc.description.abstractIn HIV-infected patients receiving rifampicin-based treatment for tuberculosis (TB), the dosage of lopinavir/ritonavir (LPV/r) is adjusted to prevent sub-therapeutic lopinavir concentrations. In this setting, South African clinicians were advised to administer super-boosted LPV/r (400 mg/400 mg) twice daily, instead of standard dosed LPV/r (400 mg/100 mg) twice daily. We sought to determine--in routine practice--the tolerability and HIV treatment outcomes associated with super-boosted LPV/r compared to unadjusted LPV/r in combination with rifampicin-based TB treatment.en_GB
dc.language.isoenen
dc.publisherPublic Library of Scienceen_GB
dc.rightsPublished by Public Library of Science, [url]http://www.plosone.org/[/url] Archived on this site by Open Access permission.en_GB
dc.subjectHIV/AIDSen_GB
dc.subjectTuberculosisen_GB
dc.subject.meshAdolescenten_GB
dc.subject.meshAdulten_GB
dc.subject.meshAnti-HIV Agentsen_GB
dc.subject.meshAntibiotics, Antitubercularen_GB
dc.subject.meshChilden_GB
dc.subject.meshCoinfectionen_GB
dc.subject.meshDrug Therapy, Combinationen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHIV Infectionsen_GB
dc.subject.meshHIV-1en_GB
dc.subject.meshHumansen_GB
dc.subject.meshKaplan-Meier Estimateen_GB
dc.subject.meshLopinaviren_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshRetrospective Studiesen_GB
dc.subject.meshRifampinen_GB
dc.subject.meshRitonaviren_GB
dc.subject.meshSouth Africaen_GB
dc.subject.meshTime Factorsen_GB
dc.subject.meshTuberculosisen_GB
dc.subject.meshYoung Adulten_GB
dc.titleCoadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africaen
dc.contributor.departmentMedical Unit, Médecins Sans Frontières/Doctors Without Borders, New York, New York, United States of Americaen_GB
dc.identifier.journalPloS Oneen_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.